Calmark has recruited Madeleine Skoglund as full-time CFO
Calmark Sweden AB (publ) announces today that Madeleine Skoglund has been hired as the Company’s new CFO as of September 1. Madeleine will be part of Calmark's management team.
Madeleine Skoglund takes position as new CFO at Calmark Sweden AB (publ) and, as such, also joins the management team. Madeleine succeeds Firyal Kryou, who was contracted as interim CFO in December 2021. Madeleine will take up the new role on September 1, 2022.
Madeleine has extensive experience from multiple consulting manager positions relating to finance, such as CFO, Finance Director and Head of Finance, at companies with international market presence. Most recently, she comes from Dreams Sustainable, a joint venture between the major French bank BNP and the fintech company Dreams, where she served as Head of Finance. Madeleine has a thorough experience in financial reporting, corporate governance, business planning, transformations, negotiations, and sales growth. She also holds a PGDM and Executive MBA from Henley Business School, University of Reading, in the United Kingdom.
“It gives me great pleasure to welcome Madeleine Skoglund to the team, and I look forward to working together going forward,” says Anna Söderlund, CEO of Calmark.
“I very much look forward to being involved in the management and development of Calmark, a company with thrilling times ahead,” says Madeleine Skoglund.
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company that develops and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark sells a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
Tags:
